LYMPHOCYTIC leukaemia L 1210 which arose in a DBA/2 mouse following skin paintings with methylcholanthrene (Law et al., 1949 ) is a strain specific leukaemia since it grows only in DBA/2 or related hybrid hosts. A single leukaemia cell is capable of producing progressive leukaemia and ultimate death of the DBA/2 hosts (Skipper, Schabel and Wilox, 1967) . However in spite of its strain specificity a weak immune response against this leukaemia is present even in DBA/2 mice (Mihich, 1969) . This leukaemia is also included as one of the 3 standard cancer chemotherapy screens (Leiter, Abbott and Schepartz, 1964) . Bagshawe and Currie (1968) have previously reported that intraperitoneal (i.p.) implantation of L 1210 cells pretreated with Vibrio cholerae neuraminidase (VCN) failed to kill intact (C57BLfDBA/2F1) mice whereas the pre-irradiated mice died of leukaemia. Furthermore, the recipients of VCN treated L 1210 cells showed resistance to subsequent i.p. challenge with 8 x 103 untreated L 1210 cells. In view of the above findings, it was decided to investigate more intensively the effect of neuraminidase preparations derived from Vibrio cholerae and Clostridium perfringens on the transplantability of L 1210 cells in the DBA/2 (isogenic) mice. It was also considered worth while to study the nature and magnitude of the immune response evoked by enzyme treated L 1210 cells, and to ascertain whether the induced immunity can be transferred by serum or the peritoneal exudate cells (PE) to normal DBA/2 mice.
MATERIAL AND METHODS
Mice.-Inbred, female mice of strain DBA/2 (SPF), 20-25 g (purchased from Bomholtghrd, Denmark), were used through-out this study. The mice were housed in plastic cages and provided with tap water and pelleted diet.
Leukaemia cells. Leukaemia L 1210 cells grown in suspension culture were obtained from Professor D. W. van Bekkum of the Radiological Institute Rijswijk, Netherlands. This line was originally developed from the tumour maintained in DBA/2 C57 BL mice. In our laboratory it was maintained in ascitic form by weekly i.p. transplantation of 0-1 ml of 1: 10 dilution of ascitic fluid (approximately 2 x 106 cells) in female DBA/2 mice. From a series of preliminary experiments it w-as concluded that i.p. inoculation of 10-100 cells of this line could produce progressive and fatal leukaemia in female DBA/2 hosts.
Immunosuppression of mice by cyclophosphamide treatment.-The drug cyclophosphamide is known for its immunosuppressive effect in mice (Berenbaum and Brown, 1964 ( ( Table I Bagshawe and Currie (1968) have previously found that L 1210 cells preincubated with VCN lost the property to kill normally susceptible (C 57BL/DBA/2F1) mice following i.p. inoculation, whereas all preirradiated mice died from tumour growth. The results of the present study confirm that the in vitro incubation of L 1210 cells with either VCN or CPN destroyed their capacity to induce tuLmours when implanted i.p. in intact isogenic DBA/2 mice. On the other hand, the mice whose immune status was suppressed by prior treatment with the drug cyclophosphamide, permitted the progressive growth of enzyme treated leukaemia cells, resulting eventually in their death.
Neuraminidase-induced alteration in tumour transplantability has been reported in a variety of other tumour host systems (Sanford, 1967; Lindenmann and Klein, 1967; Bagshawe, 1968, 1969 (Sanford and Condington, 1971; Sethi and Brandis, 1972 (Bekesi et al., 1971) . The failure of Bagshawe and Currie (1968) (Mihich, 1969) and as such the co-operation of this host defence response, which is relatively inefficient per se in the rejection of L 1210 leukaemia cells observed in our transfer experiments, cannot be completely ruled out. It is not yet known whether a qualitative difference exists between the immune response transferred by the serum and that transferred by PE cells.
Thus, whereas the results of the present study suggest that neuraminidase treatment of tumour cells results in an increase in their immunogenicity, it is also clear that prolonged treatment with higher enzyme concentrations can abolish the immunogenic capacity of the treated preparations. The nature of immunogen(s) involved and the exact mode of origin of highly immunogenic L 1210 cells following neuraminidase treatment is still obscure.
Whatever the nature of the immunogen(s) involved may be, neuraminidase treatment appears to be an effective procedure for producing " attenuated " vaccines for an otherwise susceptible host. The possible use of such " attenuated " tumour vaccines in the immunotherapy of cancer is obvious. In preliminary unpublished experiments we have been able to reduce successfully the incidence of lethality due to advanced L 1210 leukaemia, and have also achieved a significant prolongation in the life span of leukaemic mice by repeated interdermal injections of neuraminidase treated living leukaemia cells and also by neuraminidase treated membrane preparations of this leukaemia cell type.
